Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508337 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
A Phase 3 study, sponsored by Xigen.
- Completed
- Registry status
- Phase 3
- Development phase
- 309
- Enrollment target
NCT02508337: Completed Phase 3 study, sponsored by Xigen.
NCT02508337 is a Phase 3 study that has completed, run by Xigen. The registered enrollment target is 309 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02508337, a Phase 3 study, has completed, sponsored by Xigen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 309 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
Interventions
- DRUG Placebo
- DRUG XG-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
What the finished NCT02508337 record still lists
NCT02508337 is an interventional study that assigns participants to a tested intervention. The registered 309 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02508337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02508337 about?
NCT02508337 is a clinical study titled "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain". The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
What is the current status of trial NCT02508337?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 309 participants. The study started on 2015-07. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02508337?
The interventions under investigation include: Placebo (DRUG), XG-102 (DRUG).
Who is sponsoring clinical trial NCT02508337?
This trial is sponsored by Xigen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02508337's enrollment target sits among peer trials
309 1109th of 2000 higher than 889 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03011684 · 309 participants · Phase 3
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
- NCT06915233 · 309 participants · Phase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia